Micofenolato De Mofetilo Sandoz (Mycophenolate Mofetil)

Mycophenolate mofetil selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This blocks the synthesis of guanosine nucleotides, which are essential for the proliferation of T and B lymphocytes. By limiting lymphocyte replication, the drug dampens immune responses that can lead to graft rejection or autoimmune tissue damage.

The dosing regimen for Micofenolato De Mofetilo Sandoz is individualized and must be determined by the prescribing physician based on the patient’s clinical condition, transplant type, renal function, and concomitant medications. Patients should follow the exact dose and schedule provided by their healthcare professional.

Mycophenolate mofetil is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be used during pregnancy only when the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk and may affect the infant. Women of child‑bearing potential should use effective contraception.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with azathioprine, another antimetabolite, mycophenolate mofetil offers more selective inhibition of lymphocyte proliferation and often provides better graft‑survival rates. However, both agents share risks of bone‑marrow suppression and infection. The choice depends on the transplant protocol, patient tolerance, and physician experience.

The product should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral formulation.

Micofenolato De Mofetilo Sandoz is taken orally, usually with food or a glass of water to reduce gastrointestinal discomfort. The tablets (or capsules) should be swallowed whole and not crushed or chewed unless specifically directed by a healthcare professional.

The most serious risks include severe infections due to immunosuppression, significant reductions in white‑blood‑cell counts (leukopenia, lymphopenia), hepatic injury, and an increased long‑term risk of certain malignancies. Patients should be monitored regularly for signs of infection, blood‑cell abnormalities and liver‑function changes.

Individuals with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid the drug. It is also contraindicated in patients with active, uncontrolled infections, severe hepatic impairment, or in pregnant women unless the therapeutic benefit outweighs fetal risk. Clinicians must assess each patient’s medical history before prescribing.